Radiation therapy for oligometastatic non-small cell lung cancer

详细信息    查看全文

• 作者：Joseph K. Salama ; Steven E. Schild
• 关键词：Non ; small cell lung cancer ; Oligometastases ; SBRT ; Metastasectomy ; Radiotherapy
• 刊名：Cancer and Metastasis Reviews
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：34
• 期：2
• 页码：183-193
• 全文大小：1,025 KB
• 参考文献：1.Peters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K., Felip, E., et al. (2012). Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23(Suppl 7), vii56–vii64. doi:10.-093/?annonc/?mds226 .PubMed View Article
  2.Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., et al. (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology, 26(21), 3543-551. doi:10.-200/?JCO.-007.-5.-375 .PubMed View Article
  3.Lima, A. B., Macedo, L. T., & Sasse, A. D. (2011). Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One, 6(8), e22681. doi:10.-371/?journal.?pone.-022681 .PubMed Central PubMed View Article
  4.Soria, J. C., Mauguen, A., Reck, M., Sandler, A. B., Saijo, N., Johnson, D. H., et al. (2013). Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Annals of Oncology, 24(1), 20-0. doi:10.-093/?annonc/?mds590 .PubMed View Article
  5.Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361(10), 947-57. doi:10.-056/?NEJMoa0810699 .PubMed View Article
  6.Kwak, E. L., Bang, Y. J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., et al. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New England Journal of Medicine, 363(18), 1693-703. doi:10.-056/?NEJMoa1006448 .PubMed Central PubMed View Article
  7.Shaw, A. T., Ou, S. H., Bang, Y. J., Camidge, D. R., Solomon, B. J., Salgia, R., et al. (2014). Crizotinib in ROS1-rearranged non-small-cell lung cancer. New England Journal of Medicine. doi:10.-056/?NEJMoa1406766 .
  8.Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., et al. (1990). A randomized trial of surgery in the treatment of single metastases to the brain. New England Journal of Medicine, 322(8), 494-00.PubMed View Article
  9.Kocher, M., Soffietti, R., Abacioglu, U., Villa, S., Fauchon, F., Baumert, B. G., et al. (2011). Adjuvant whole
  ain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-6001 study. Journal of Clinical Oncology, 29(2), 134-41. doi:10.-200/?JCO.-010.-0.-655 .PubMed Central PubMed View Article
  10.Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., et al. (2004). Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet, 363(9422), 1665-672.PubMed View Article
  11.Patel, P. R., Yoo, D. S., Niibe, Y., Urbanic, J. J., & Salama, J. K. (2012). A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer. Pulmonary Medicine, 2012, 480961. doi:10.-155/-012/-80961 .PubMed Central PubMed View Article
  12.Lewis, SL., Porceddu, S., Nakamura, N., Palma, D., Lo, S., Hoskin, P., et al. (2014). Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 Radiation Oncologists. American Journal of Clinical Oncology. doi:10.-097/?COC.-000000000000169-/span> .
  13.Hellman, S., & Weichselbaum, R. R. (1995). Oligometastases. Journal of Clinical Oncology, 13(1), 8-0.PubMed
  14.Rubin, P., & Green, J. (1968). Solitary metastases. Springfield, IL: C. C. Thomas.
  15.Cheruvu, P., Metcalfe, S. K., Metcalfe, J., Chen, Y., Okunieff, P., & Milano, M. T. (2011). Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer. [Comparative Study]. Radiation Oncology, 6, 80. doi:10.-186/-748-717X-6-80 .PubMed Central PubMed View Article
  16.Albain, K. S., Crowley, J. J., LeBlanc, M., & Livingston, R. B. (1991). Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. Journal of Clinical Oncology, 9(9), 1618-626.PubMed
  17.Torok, J., Kelsey, C. R., & Salama, J. K. Patterns of Distant Metastases in Surgically Managed Early Stage Non-Small Cell Lung Cancer. In 55th Annual ASTRO Meeting., Atlanta, Georgia., September 22-5, 2013 2013
  18.Hasselle, M. D., Haraf, D. J., Rusthoven, K. E., Golden, D. W., Salgia, R., Villaflor, V. M., et al. (2012). Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. [Research Support, Non-U.S. Gov’t]. Journal of Thoracic Oncology, 7(
• 作者单位：Joseph K. Salama (1)
  Steven E. Schild (2)
  
  1. Department of Radiation Oncology, Duke University, Box 3085, Durham, NC, 27710, USA
  2. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, USA
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Cancer Research
  
• 出版者：Springer Netherlands
• ISSN：1573-7233

文摘

Interest has been increasing in the treatment of non-small cell lung cancer (NSCLC) patients with limited or oligometastatic disease. Surgery has historically been used to remove non-small cell lung cancer metastases, but recent developments including advanced radiotherapy planning and delivery techniques, often called stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy (SABR), has been associated with high rates of treated metastasis control. Therefore, given common comorbid disease, often precluding surgery, an increasing number of oligometastatic NSCLC patients are receiving radiation for ablation of all disease. Early results have reported favorable survival for some, with improved median survival, and approximately 25?% alive long term. Patients with fewer metastases, those treated to all known cancerous sites, and longer disease-free intervals tend to have better outcomes. While promising, better clinical criteria are needed to optimize patient selection. The biologic underpinnings of the oligometastatic state are beginning to be demonstrated with specific microRNAs being associated with limited or no progression both in human samples and murine models. Clinical trials are ongoing to improve the techniques used to deliver radiotherapy for NSCLC oligometastases. Ideally, randomized studies will need to be conducted to demonstrate the utility of these treatments suggested by the uncontrolled studies to date. In lieu of these, data presented here may help guide clinicians as to appropriate patient selection.